Autologous hematopoietic stem cell transplant (HSCT)

PROCEDURE2 trials

Sponsors

Ronald Levy, Otsuka Pharmaceutical Development & Commercialization, Inc.

Conditions

Lymphoma, Mantle-CellMultiple Myeloma

Phase 2

Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL

CompletedNCT00490529

Ronald LevyLymphoma, Mantle-Cell

Start: 2009-08-31End: 2017-12-14Updated: 2020-01-13

IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients

CompletedNCT01009840

Otsuka Pharmaceutical Development & Commercialization, Inc.Multiple Myeloma

Start: 2010-05-31End: 2012-03-31Updated: 2014-09-25

Related Papers

Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial

The Journal of Experimental Medicine2020-06-1937 citations

PHASE I/II CLINICAL TRIAL OF AN ACTIVATED WHOLE TUMOR CELL VACCINE FOLLOWED BY TRANSFER OF IMMUNE T CELLS IN PATIENTS WITH MANTLE CELL LYMPHOMA

Hematological Oncology2017-06-012 citations

Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis

Blood2015-12-033 citations

High-Throughput Sequencing Of T Cell Receptors Detects Signatures Of T Cell Repertoire That Predict MRD Status In Patients With Mantle Cell Lymphoma Undergoing Immunotransplantation

Blood2013-11-15